SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cohen Hannah)
 

Sökning: WFRF:(Cohen Hannah) > Autologous Transpla...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008161naa a2200841 4500
001oai:DiVA.org:uu-358199
003SwePub
008180831s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:138548517
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3581992 URI
0247 a https://doi.org/10.1016/j.bbmt.2017.12.7712 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1385485172 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Casulo, Carlau Univ Rochester, Wilmot Canc Inst, New York, NY USA4 aut
2451 0a Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure :b A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
264 1b Elsevier BV,c 2018
338 a print2 rdacarrier
520 a Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Follicular lymphoma
653 a Early therapy failure
653 a Autologous transplantation
653 a Early transplant
653 a Rituximab
653 a Chemoimmunotherapy
7001 a Friedberg, Jonathan W.u Univ Rochester, Wilmot Canc Inst, New York, NY USA4 aut
7001 a Ahn, Kwang W.u Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA4 aut
7001 a Flowers, Christopheru Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA4 aut
7001 a DiGilio, Alyssau Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA4 aut
7001 a Smith, Sonali M.u Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA4 aut
7001 a Ahmed, Sairahu Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA4 aut
7001 a Inwards, Davidu Mayo Clin, Div Hematol, Rochester, MN USA4 aut
7001 a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riydah, Saudi Arabia4 aut
7001 a Chen, Andy, Iu Oregon Hlth & Sci Univ, Blood & Marrow Transplant Program, Portland, OR 97201 USA4 aut
7001 a Choe, Hannahu Weill Cornell Med Coll, Blood & Marrow Transplant Program, New York, NY USA4 aut
7001 a Cohen, Jonathonu Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA4 aut
7001 a Copelan, Edwardu Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA4 aut
7001 a Farooq, Umaru Univ Iowa, Dept Med, Iowa City, IA 52242 USA4 aut
7001 a Fenske, Timothy S.u Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA4 aut
7001 a Freytes, Cesaru Texas Transplant Inst, Blood & Marrow Transplant Program, San Antonio, TX USA4 aut
7001 a Gaballa, Samehu Thomas Jefferson Univ Hosp, Blood & Marrow Transplant Program, Philadelphia, PA 19107 USA4 aut
7001 a Ganguly, Siddharthau Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS 66103 USA4 aut
7001 a Jethava, Yogeshu Univ Arkansas Med Sci, Blood & Marrow Transplant Program, Little Rock, AR 72205 USA4 aut
7001 a Kamble, Rammurti T.u Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA4 aut
7001 a Kenkre, Vaishalee P.u Univ Wisconsin, Div Hematol & Oncol, Madison, WI USA4 aut
7001 a Lazarus, Hillardu Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA4 aut
7001 a Lazaryan, Aleksandru Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Rezvani, Andrew R.u Stanford Hlth Care, Blood & Marrow Transplant Program, Stanford, CA USA4 aut
7001 a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA4 aut
7001 a Seo, Sachikou East Hosp, Natl Canc Res Ctr, Chiba, Japan4 aut
7001 a Shah, Gunjan L.u Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA4 aut
7001 a Shah, Ninau Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA4 aut
7001 a Solh, Melhamu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA4 aut
7001 a Sureda, Annau Inst Catala Oncol Hosp, Hematol Dept, Barcelona, Spain4 aut
7001 a William, Basemu Ohio State Med Ctr, James Canc Ctr, Columbus, OH USA4 aut
7001 a Cumpston, Aaronu West Virginia Univ Hosp, Blood & Marrow Transplant Program, Morgantown, WV USA4 aut
7001 a Zelenetz, Andrew D.u Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA4 aut
7001 a Link, Brian K.u Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA4 aut
7001 a Hamadani, Mehdiu Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA4 aut
7102 a Univ Rochester, Wilmot Canc Inst, New York, NY USAb Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA4 org
7730 t Biology of blood and marrow transplantationd : Elsevier BVg 24:6, s. 1163-1171q 24:6<1163-1171x 1083-8791x 1523-6536
8564 u http://www.bbmt.org/article/S1083879117316750/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358199
8564 8u https://doi.org/10.1016/j.bbmt.2017.12.771
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:138548517

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy